Gilead Sciences, Inc. has historically focused on virology, with blockbuster products for HIV, hepatitis C and hepatitis B, but more recently has looked to broaden its therapeutic focus, particularly into oncology. Now the company appears to be re-emphasizing its core strength, signing a 12-year collaboration on 17 October with Assembly Biosciences, Inc. that will give it opt-in rights on all current and future pipeline candidates across herpesvirus, hepatis B virus (HBV) and hepatitis D.
Key Takeaways
-
Gilead makes $100m upfront commitment, including an equity purchase, in Assembly to collaborate on novel antivirals for herpesvirus, hep B and hep D.
-
Under the agreement, Gilead can opt in to take over any Assembly pipeline asset, including future R&D discoveries, over a 12-year term
Following some development setbacks in 2020 and 2021 that left it with nothing currently in active clinical development, Assembly has been attempting its own transformation, going back to R&D to identify novel approaches to viral diseases. (Also see "Assembly Looks To Quickly Move Past ABI-H2158 Discontinuation" - Scrip, 2 September, 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
